Sandoz Can't Cancel Sanofi Unit's Autoimmune Disorder Drug

By Hanna Vioque ( April 10, 2026, 5:04 PM BST) -- European appellate officials have upheld a Sanofi unit's patent for a drug treating autoimmune disorders despite objections from Sandoz because the specific enzyme blockers it uses were structurally different from those in existing treatments....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login